Good MorningEquities moved higher on Wednesday despite a hot reading of the CPI. The CPI came in at 0.5% for the month or up a tenth hotter than expected with similar strength at the core and YOY levels. The takeaway is that inflation continues to rise and is leaving the FOMC no choice but to raise rates. Based on Jerome Powell’s testimony to Congress it looks like the Fed will be raising rates at a much quicker pace than ever indicated. According to the CME’s FedWath Tool, a rate hike is all but assured at the March FOMC meeting.
Today’s action will be driven by the PPI. The Producer Price Index is expected to subside from the previous month but could easily come in hotter than expected. Even so, with CPI already at record levels, a cool read on the PPI will do little to alter the outlook. The question is how will the market react?
Featured: Under-the-radar company receives rare "All In" buy signal (Motley Fool) 
|
Markets | | | MarketBeat uses the latest technology to provide proprietary, comprehensive, accurate, and up-to-the-minute financial data. And because this information can be overwhelming, MarketBeat provides investors with the ability to input their stocks of interest (either those that are in their portfolio or on their watchlist) Read the Full Story |
|
From Our PartnersThis company offers a massive market, significant growth and a huge opportunity for everyday investors...
Why? Because they're publicly traded and specialize in a breakthrough medical discovery...
Keep your eyes on this stock in 2022 - it could be huge. | | Click here for the details on this early investment opportunity |
|
Politics | | | India and Britain have formally launched talks to pursue a free trade deal that is expected to boost their trade by billions, making it one of the most ambitious negotiations to take place after Brexit Read the Full Story |
|
Stocks | | | Whether you are just getting started on your investing journey or you are an experienced trader looking to load up heavy on stocks priced at reasonable levels, focusing on stocks under $100 per share can really help you make the most out of every dollar you put to work. Read the Full Story |
|
From Our PartnersSee under the hood of this Revolutionary Rapid Wealth Multiplier system and access the names of TWELVE New Stocks primed to skyrocket over time...
If retirement is sneaking on you fast...
And you have a way to go before securing a decent nest egg...
You should act ASAP. | | Click here to find out more. |
|
Politics | | | Shares were mostly lower in Asia on Thursday after the latest report of surging prices in the U.S. appeared to keep the Federal Reserve on track to raise interest rates in coming months.
London, Paris, Tokyo and Shanghai were lower while Sydney and Hong Kong advanced.
... Read the Full Story |
|
Politics | | | Shares were mostly lower in Asia on Thursday after the latest report of surging prices in the U.S. appeared to keep the Federal Reserve on track to raise interest rates in coming months.
London, Paris, Tokyo and Shanghai were lower while Sydney and Hong Kong advanced.
... Read the Full Story |
|
From Our PartnersDo you wait for an entire year for your stock portfolio to go up 10%? There's a better way. Had you used Money Calendar trades, you could have grown your account 166% faster than the S&P 500 over the last four years. It's still not too late though. There are 10 more Money Calendar trades scheduled to go up between now and January 24. | | Get the free tickers here before it's too late. |
|
Politics | | | Europe’s natural gas crisis isn't letting up. Reserves are low. Prices are high. Utility customers are getting hit with higher bills. Major Russian supplier Gazprom isn't selling gas like it used to.
It all raises the question: How exactly is Europe, which imports most of its energy,... Read the Full Story |
|
Tech | | | Taiwan Semiconductor Manufacturing Co., the biggest contract manufacturer of processor chips, says its quarterly profit rose 16.4% over a year earlier to $6 billion amid surging demand for chips for smartphones and other electronics Read the Full Story |
|
Markets | | |
Energy drink maker Monster Beverage (NASDAQ: MNST) shares have been rallying despite the market sell-off on merger speculation. The rising costs of aluminum, shipping costs and supply chain disruptions hurt margins resulting in a miss on in its Q3 2021 earnings report. While the Company doesn&rsqu... Read the Full Story |
|
Markets | | | Albertsons Companies (NYSE: ACI) has been working hard on improving its business over the past year or two and those efforts are showing up in the results. The company reported better than expected earnings for FQ3 and gave favorable guidance but it was not enough to get the stock moving higher. Read the Full Story |
|
Markets | | | There's no secret that real estate was a dizzying rollercoaster in 2021. If you didn't dip into real estate investing last year, here's a quick summary of what happened:
The pandemic completely bent the home-buying process last year. What to do about real estate in 2022? Here are some options. Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. | | View Today's Stock Pick |
|
